Clinical Trials on Vulvovaginal Atrophy in New Zealand

Total 322 results

GTx

Completed

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer | Muscle Wasting

United States
PepGen Inc

Recruiting

A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment (CONNECT1-EDO51)

Duchenne Muscular Dystrophy

Canada
NYU Langone Health
Michael J. Fox Foundation for Parkinson's Research

Completed

Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease

Parkinson Disease | Multiple System Atrophy | REM Sleep Behavior Disorder | Pure Autonomic Failure | Dementia With Lewy Bodies

United States
Ultragenyx Pharmaceutical Inc

Completed

A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (GNE Myopathy)

Hereditary Inclusion Body Myopathy | GNE Myopathy

United States, Israel
Stony Brook University

Active, not recruiting

A Pilot Biomarker Study Assessing Alpha-synuclein Aggregates Across Biofluid Reservoirs in Patients With Synucleinopathies

Parkinson Disease | Multiple System Atrophy | Normal Pressure Hydrocephalus | Rapid Eye Movement Sleep Behavior Disorder

United States
Opexa Therapeutics, Inc.

Completed

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis (Abili-T)

Multiple Sclerosis | Autoimmune Diseases of the Nervous System | Disease Progression | Secondary Progressive Multiple Sclerosis | Brain Atrophy

United States, Canada
Santhera Pharmaceuticals

No longer available

Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States
Ultragenyx Pharmaceutical Inc

Completed

An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy

GNE Myopathy | Hereditary Inclusion Body Myopathy (HIBM)

United States, Israel
University of Rochester
University of Colorado, Denver; Massachusetts General Hospital; Stanford University

Recruiting

Community Outreach for Palliative Engagement -- Parkinson Disease (COPE-PD)

Parkinson Disease | Multiple System Atrophy | Corticobasal Degeneration | Progressive Supranuclear Palsy | Parkinson's Disease and Parkinsonism | Dementia With Lewy Bodies | Vascular Parkinsonism | Parkinson Disease Dementia | Lewy Body Parkinsonism

United States
aTyr Pharma, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy

Facioscapulohumeral Muscular Dystrophy (FSHD)

United States, Netherlands, France, Italy
University of Rochester
National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry

Muscular Dystrophy | Myotonic Dystrophy Type 2 | Myotonic Dystrophy Type 1 | Myotonic Dystrophy | Facioscapulohumeral Muscular Dystrophy | Steinert's Disease | Congenital Myotonic Dystrophy | PROMM (Proximal Myotonic Myopathy) | Myotonic Muscular Dystrophy

United States
PTC Therapeutics

Completed

An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort

Duchenne Muscular Dystrophy

United States
PepGen Inc

Recruiting

Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1 (FREEDOM-DM1)

Myotonic Dystrophy 1

United States, Canada
PTC Therapeutics

Completed

A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States
University of Rochester
National Institute of Neurological Disorders and Stroke (NINDS); University... and other collaborators

Completed

Multicenter Observational Study of Myotonic Dystrophy Type 1 (MOS-DM1/POP)

Myotonic Dystrophy Type 1

United States
Virginia Commonwealth University

Recruiting

DMCRN-02-001: Assessing Pediatric Endpoints in DM1 (ASPIRE-DM1)

Congenital Myotonic Dystrophy | Childhood Myotonic Dystrophy | CDM | CHDM

United States, Italy
California Pacific Medical Center Research Institute
University of Pittsburgh; Duke University; National Institute on Aging (NIA); University... and other collaborators

Recruiting

Trial of Parkinson's And Zoledronic Acid (TOPAZ)

Parkinson Disease | Osteoporosis | Parkinsonism | Multiple System Atrophy | Progressive Supranuclear Palsy | Parkinson's Disease and Parkinsonism | Dementia With Lewy Bodies | Atypical Parkinsonism | Vascular Parkinsonism

United States
University of Kansas Medical Center
National Institute of Neurological Disorders and Stroke (NINDS)

Active, not recruiting

Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD

Facioscapulohumeral Muscular Dystrophy

United States
Jonathann Kuo, MD

Active, not recruiting

Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID (DSBLongCOVID)

SARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditions

United States
Leadiant Biosciences, Inc.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Active, not recruiting

Multi-Center Study of ManNAc for GNE Myopathy (MAGiNE)

GNE Myopathy

United States
Pfizer

Active, not recruiting

Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy

Muscular Dystrophy, Duchenne

United States, Australia
PTC Therapeutics

Completed

A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Duchenne Muscular Dystrophy

United States
Ultragenyx Pharmaceutical Inc

Terminated

A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment

Hereditary Inclusion Body Myopathy | GNE Myopathy | Inclusion Body Myopathy 2 | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

Canada, United States, Bulgaria
Sarepta Therapeutics, Inc.

Completed

Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy

Muscular Dystrophy, Duchenne

United States
New York Stem Cell Foundation Research Institute

Recruiting

NYSCF Scientific Discovery Biobank

PTSD | Multiple Sclerosis | Cervical Cancer | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes | Macular Degeneration | Diabetes Mellitus, Type 1 | Parkinson Disease | Amyotrophic Lateral Sclerosis | Dementia | Ovarian Cancer | Alzheimer Disease | ALS | Vulvar Cancer | Post Traumatic Stress Disorder | Lewy Body Disease and other conditions

United States
Ionis Pharmaceuticals, Inc.

Completed

A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1

Myotonic Dystrophy Type 1

United States
Sarepta Therapeutics, Inc.
Hoffmann-La Roche

Enrolling by invitation

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study (EXPEDITION)

Duchenne Muscular Dystrophy

United States
BioMarin Pharmaceutical

Terminated

A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects

Muscular Dystrophies

United States, Canada
University of Kansas Medical Center
Hoffmann-La Roche; Seattle Children's Hospital; University of Rochester; University... and other collaborators

Recruiting

Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) (MOVE FSHD)

FSHD

United States, Canada, United Kingdom
University of Rochester
National Institute of Neurological Disorders and Stroke (NINDS); Newcastle... and other collaborators

Completed

Finding the Optimum Regimen for Duchenne Muscular Dystrophy (FOR-DMD)

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Germany, Italy
Avidity Biosciences, Inc.

Active, not recruiting

Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients (MARINA-OLE)

Nervous System Diseases | Genetic Diseases, Inborn | Musculoskeletal Diseases | Muscular Diseases | Neuromuscular Diseases | Neurodegenerative Diseases | Muscular Dystrophies | Muscular Disorders, Atrophic | Heredodegenerative Disorders, Nervous System | Myotonic Dystrophy | Myotonic Disorders | Myotonic Dystrophy... and other conditions

United States
Insmed Incorporated
Muscular Dystrophy Association

Completed

Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

Myotonic Dystrophy Type 1

United States
GlaxoSmithKline

Completed

A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD) (DMD114876)

Muscular Dystrophies

United States
Sarepta Therapeutics, Inc.

Completed

Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy (DMD)

United States
GlaxoSmithKline

Completed

Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy

Muscular Dystrophies

Germany, Belgium, Turkey, Netherlands, Spain, Israel, Australia, France, United Kingdom
Sarepta Therapeutics, Inc.

Completed

Study of Eteplirsen in DMD Patients (PROMOVI)

Duchenne Muscular Dystrophy (DMD)

United States
Fulcrum Therapeutics

Active, not recruiting

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

Facioscapulohumeral Muscular Dystrophy (FSHD)

United States, Canada, France, Spain
Fulcrum Therapeutics

Completed

Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) (FSHD)

Facioscapulohumeral Muscular Dystrophy (FSHD)

United States, Canada, France, Spain
Hoffmann-La Roche

Completed

Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Belgium, Canada, Australia, Japan, France, Netherlands, Spain, Argentina, Germany, Italy, United Kingdom, Sweden
Avidity Biosciences, Inc.

Completed

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients (MARINA)

Myotonic Dystrophy | Myotonic Disorders | Myotonic Dystrophy Type 1 (DM1) | Myotonic Dystrophy 1 | Myotonic Muscular Dystrophy | DM1 | Dystrophy Myotonic | Steinert Disease

United States
CND Life Sciences

Completed

Synuclein-One Study

Parkinson Disease | Multiple System Atrophy | Pure Autonomic Failure | Dementia With Lewy Bodies

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

Facioscapulohumeral Muscular Dystrophy

United States, Spain, Canada
Newcastle-upon-Tyne Hospitals NHS Trust
Jain Foundation

Active, not recruiting

Clinical Outcome Study for Dysferlinopathy (Jain COS)

Dysferlinopathy | LGMD2B Now Classified as LGMDR2 | Miyoshi Myopathy

Korea, Republic of, Chile, Spain, United States, Denmark, France, Italy, Japan, United Kingdom
Wave Life Sciences Ltd.

Terminated

Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)

Duchenne Muscular Dystrophy

United States, Belgium, United Kingdom, Czechia, Canada, France, Italy, Sweden
Ultragenyx Pharmaceutical Inc

Completed

Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) (GNEM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
NYU Langone Health

Recruiting

Natural History Study of Synucleinopathies

Parkinson Disease | Multiple System Atrophy | Neurogenic Orthostatic Hypotension | REM Sleep Behavior Disorder | Pure Autonomic Failure | Dementia With Lewy Bodies | Patients With Synucleinopathies | Shy-Drager Disease

Korea, Republic of, United States, Argentina, Spain
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating MYO-029 in Adult Muscular Dystrophy

Becker Muscular Dystrophy | Facioscapulohumeral Muscular Dystrophy | Limb-Girdle Muscular Dystrophy

United States
Ultragenyx Pharmaceutical Inc

Terminated

Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy | GNE Myopathy | Distal Myopathy With Rimmed Vacuoles | Distal Myopathy, Nonaka Type | Quadriceps Sparing Myopathy

United States, Canada, United Kingdom, Israel, Italy, Bulgaria, France
Capricor Inc.

Recruiting

A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-3)

Nervous System Diseases | Genetic Diseases, Inborn | Genetic Diseases, X-Linked | Muscular Diseases | Neuromuscular Diseases | Muscular Dystrophies | Muscular Disorders, Atrophic | Muscular Dystrophy, Duchenne

United States
Sarepta Therapeutics, Inc.
Hoffmann-La Roche

Recruiting

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) (ENVISION)

Duchenne Muscular Dystrophy

Belgium, United States, Japan, Spain, Italy, United Kingdom

Clinical Trials on Vulvovaginal Atrophy in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations